Lantern Pharma secures Taiwan clearances for Phase II NSCLC study

Phase 2LP-300Positive

AI Analysis

Summary

Lantern Pharma has obtained regulatory and IRB clearances in Taiwan to begin Part 2 of its Phase II HARMONIC trial evaluating LP-300 combined with carboplatin and pemetrexed in patients with advanced NSCLC who are never-smokers.

Clinical Trial Data

Phase

Phase II

Outcome Details

Secured regulatory and IRB clearances in Taiwan to initiate Part 2 of Phase II HARMONIC trial

Importance:5/10

Sentiment:

0.60

Phase IINSCLCRegulatory ClearanceTaiwanLP-300HARMONIC trial

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on October 8, 2026 10:05 AM

Read Original